Other News Releases in Health Care & Hospitals
Landauer, Inc. Increases Regular Cash Dividend and Declares First Quarter Payment
New Breast MRI Technology Enables Enhanced Breast Cancer Detection
National Hot Rod Association Mandates Eject Helmet Removal System for 2010
Other News Releases in Trade Show News
Viacom President and Chief Executive Officer Philippe Dauman to Speak at the UBS Global Media and Communications Conference
Covanta Holding Corporation to Present at the J. P. Morgan SMid Cap Conference 2009
Television Company Belo Corp. (BLC) to Present at UBS Global Media & Communications Conference
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
See more news releases in: Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News
Cadence Pharmaceuticals' CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, November 4, 2009 at 2:45pm Eastern Time (11:45am Pacific Time) during the Oppenheimer 20th Annual Healthcare Conference at the Waldorf Astoria Hotel in New York City.
The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.
Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.
Contacts: William R. LaRue
SVP, CFO
Cadence Pharmaceuticals, Inc.
858-436-1400
SOURCE Cadence Pharmaceuticals, Inc.